Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Given Average Recommendation of "Moderate Buy" by Brokerages

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Get Free Report) has been given an average recommendation of "Moderate Buy" by the twenty-six research firms that are covering the firm, Marketbeat.com reports. One investment analyst has rated the stock with a sell rating, four have issued a hold rating and twenty-one have issued a buy rating on the company. The average 1-year target price among brokerages that have issued a report on the stock in the last year is $319.17.

A number of brokerages recently commented on ALNY. Stifel Nicolaus lifted their price target on Alnylam Pharmaceuticals from $300.00 to $345.00 and gave the stock a "buy" rating in a report on Monday, March 31st. UBS Group upped their price objective on Alnylam Pharmaceuticals from $331.00 to $349.00 and gave the company a "buy" rating in a research note on Friday, May 2nd. Chardan Capital raised their target price on Alnylam Pharmaceuticals from $300.00 to $325.00 and gave the stock a "buy" rating in a research report on Friday, May 2nd. HC Wainwright reaffirmed a "buy" rating and set a $500.00 price objective on shares of Alnylam Pharmaceuticals in a report on Wednesday, April 2nd. Finally, StockNews.com upgraded shares of Alnylam Pharmaceuticals from a "hold" rating to a "buy" rating in a research note on Thursday, May 8th.

Alnylam Pharmaceuticals Stock Down 1.2%

ALNY stock traded down $3.33 during midday trading on Friday, reaching $266.86. 723,502 shares of the company's stock traded hands, compared to its average volume of 905,848. Alnylam Pharmaceuticals has a 52 week low of $144.73 and a 52 week high of $304.39. The company has a market cap of $34.80 billion, a price-to-earnings ratio of -122.98 and a beta of 0.17. The company has a quick ratio of 2.71, a current ratio of 2.78 and a debt-to-equity ratio of 15.27. The firm's fifty day moving average price is $251.33 and its 200-day moving average price is $253.69.

Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) last posted its earnings results on Thursday, May 1st. The biopharmaceutical company reported ($0.44) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.37) by ($0.07). The firm had revenue of $594.19 million for the quarter, compared to analysts' expectations of $584.32 million. During the same period last year, the firm posted ($0.16) EPS. Alnylam Pharmaceuticals's quarterly revenue was up 20.2% on a year-over-year basis. As a group, sell-side analysts forecast that Alnylam Pharmaceuticals will post -1.7 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other news, CMO Pushkal Garg sold 1,561 shares of the company's stock in a transaction on Friday, February 14th. The stock was sold at an average price of $255.17, for a total transaction of $398,320.37. Following the sale, the chief marketing officer now owns 13,537 shares of the company's stock, valued at approximately $3,454,236.29. This represents a 10.34% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Kevin Joseph Fitzgerald sold 663 shares of the firm's stock in a transaction that occurred on Friday, February 14th. The shares were sold at an average price of $255.21, for a total transaction of $169,204.23. Following the completion of the sale, the executive vice president now directly owns 14,321 shares in the company, valued at approximately $3,654,862.41. This trade represents a 4.42% decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 7,392 shares of company stock worth $1,875,627. Company insiders own 1.50% of the company's stock.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the stock. Jennison Associates LLC purchased a new stake in Alnylam Pharmaceuticals in the 4th quarter valued at approximately $61,160,000. Strategic Financial Concepts LLC acquired a new position in Alnylam Pharmaceuticals during the fourth quarter worth about $41,529,000. Truist Financial Corp grew its holdings in Alnylam Pharmaceuticals by 136.6% during the 4th quarter. Truist Financial Corp now owns 4,398 shares of the biopharmaceutical company's stock valued at $1,035,000 after buying an additional 2,539 shares during the last quarter. Sumitomo Mitsui Trust Group Inc. raised its stake in Alnylam Pharmaceuticals by 3.0% in the 4th quarter. Sumitomo Mitsui Trust Group Inc. now owns 286,703 shares of the biopharmaceutical company's stock valued at $67,464,000 after purchasing an additional 8,462 shares during the last quarter. Finally, Assenagon Asset Management S.A. lifted its stake in shares of Alnylam Pharmaceuticals by 13.0% during the fourth quarter. Assenagon Asset Management S.A. now owns 19,918 shares of the biopharmaceutical company's stock valued at $4,687,000 after buying an additional 2,285 shares during the period. Institutional investors and hedge funds own 92.97% of the company's stock.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.